You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

ID: GL-END-C50-35 aoû 2023
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
F.C. Wright, J. Lipa, T. Zhong, E. Piliotis, Z. Ghorab, P. Stotland, M. Lee , Diagnosis and Treatment of BIA-ALCL Guideline Development Group

Guideline Objective

The objectives of this guideline are to provide recommendations on diagnosing and treating Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). The recommendations are based on the National Comprehensive Cancer Network (NCCN) Version 2.2022 T-Cell Lymphomas Guideline on BIA-ALCL.

Patient Population

Patients with suspected or confirmed BIA-ALCL.

Intended Guideline Users

The guideline document will support providers in diagnosing and treating patients with BIA-ALCL.

pdf download Full Report (PDF) (372.89 Ko)